Revenue and Profitability - Total revenue for Q3 2022 reached CNY 2,768,208,563.01, an increase of 37.31% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 20.95% to CNY 375,674,760.35 for Q3 2022[4] - Operating revenue increased to ¥7,402,793,998.96, a year-on-year growth of 39.63% compared to ¥5,301,532,904.44[8] - Total revenue for the nine months ended September 30, 2022, was RMB 7,402,794 thousand, an increase from RMB 5,301,533 thousand in the same period of 2021, representing a growth of 32.5%[46] - Net profit for the current period is 944,178,254.54, down from 1,003,928,223.19 in the previous period, indicating a decrease of approximately 5.9%[35] - The company reported a profit attributable to equity holders of RMB 961,107 thousand for the nine months ended September 30, 2022, down from RMB 1,040,063 thousand in 2021, indicating a decline of 7.6%[51] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 1,395,070,031.14 for the year-to-date period, a decrease of 1.46% compared to the previous year[4] - Cash and cash equivalents decreased by 42.36% to ¥2,042,501,533.84 from ¥3,543,819,700.44, a reduction of ¥1,501,318,200[8] - Cash inflow from operating activities is 7,076,581,251.14, an increase from 5,410,437,911.75 in the previous period, reflecting a growth of approximately 30.8%[37] - Cash outflow from investment activities is 5,208,210,770.23, down from 7,505,559,923.92 in the previous period, indicating a reduction of approximately 30.5%[42] - Cash and cash equivalents decreased to RMB 1,780,290 thousand from RMB 3,526,577 thousand at the beginning of the year, indicating a decline of 49.5%[47] Assets and Liabilities - The total assets as of the end of Q3 2022 were CNY 19,706,904,963.16, reflecting a 7.17% increase from the end of the previous year[4] - Total liabilities increased to CNY 9,165,741,734.83 from CNY 8,093,817,609.58, marking a rise of 13.2%[26] - Total non-current assets increased to RMB 13,054,092 thousand as of September 30, 2022, up from RMB 9,745,622 thousand at the beginning of the year, marking a growth of 33.7%[47] - The company’s total assets less current liabilities amounted to RMB 16,060,504 thousand, an increase from RMB 15,407,128 thousand at the beginning of the year[47] Equity and Shareholder Information - The total equity attributable to shareholders was CNY 10,401,703,789.08, a 2.69% increase from the end of the previous year[4] - The total number of common shareholders at the end of the reporting period was 34,592[18] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 16.88% and Shenzhen Xinchongkang Investment Partnership holding 16.79%[19] Expenses and Cost Management - Total operating costs increased by 39.81% to ¥4,701,717,656.76 from ¥3,362,990,019.03, in line with revenue growth[14] - Sales expenses increased by 56.20% to ¥163,039,241.44 compared to ¥104,381,393.02 in the same period last year[15] - Management expenses rose by 73.19% to ¥1,036,265,811.81 from ¥598,348,091.85 year-on-year, primarily due to increased personnel costs and acquisitions[15] - R&D expenses grew by 61.55% to ¥177,468,493.98, up from ¥109,851,832.35, reflecting the company's commitment to enhancing R&D capabilities[15] Profit Margins and Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.3171, down 20.71% year-on-year[4] - The net profit excluding non-recurring gains and losses increased by 8.79% to CNY 377,837,497.51 for Q3 2022[4] - Basic earnings per share for the current period is 0.8118, down from 0.8754 in the previous period, representing a decrease of approximately 7.3%[36] Government Support and Subsidies - The company received government subsidies amounting to CNY 11,466,691.04 during the reporting period[6]

Financial Performance - The total revenue for the six months ended June 30, 2022, was approximately RMB 4,634.6 million, an increase of about RMB 1,349.1 million or 41.1% compared to the same period in 2021[8]. - The gross profit for the same period was RMB 1,613.1 million, reflecting a growth of 35.6% from RMB 1,189.7 million in the previous year[8]. - The profit attributable to equity holders of the parent company was approximately RMB 585.4 million, up by 3.6% from RMB 564.8 million in the prior year[9]. - The adjusted net profit for the period was RMB 812.1 million, representing a 24.7% increase from RMB 651.4 million in the previous year[9]. - The net cash flow from operating activities was approximately RMB 858.8 million, a slight increase of 1.6% compared to RMB 845.1 million in the same period last year[9]. - Basic earnings per share were approximately RMB 0.4941, up 4.0% from approximately RMB 0.4751 for the six months ended June 30, 2021[22]. - The company reported a profit of RMB 1,191,068,000 for the six months ending June 30, 2022, compared to RMB 794,177,000 for the same period in 2021, representing a year-over-year increase of approximately 50%[84]. - The total comprehensive income for the period was RMB 547,136,000, compared to RMB 564,837,000 in the previous period, indicating a slight decline[86]. Revenue Breakdown - Revenue from North American clients accounted for 65.6%, while European clients contributed 13.6%, and Chinese clients contributed 17.7%[11]. - The laboratory services segment generated revenue of RMB 2,860.1 million, a 41.1% increase year-on-year, with a gross margin of 43.4%[12]. - CMC (small molecule CDMO) services achieved revenue of RMB 1,084.6 million, a year-on-year increase of 42.3%, with a gross margin of 32.9%, down 3.6 percentage points from the previous year[13]. - Clinical research services generated revenue of RMB 584.5 million, up 38.3% year-on-year, with a gross margin of 5.1%, down 9.0 percentage points from the previous year[14]. - The company’s large molecule and cell and gene therapy services reported revenue of RMB 95.5 million, a 33.2% increase year-on-year, but with a gross margin of -19.8% due to high operational costs[16]. Operational Highlights - The company introduced over 400 new clients in the first half of 2022, expanding its customer base significantly[11]. - The company operates in China, the United States, and the United Kingdom, employing over 17,000 staff[6]. - The company has over 800 ongoing clinical trial projects and collaborates with more than 600 hospitals and clinical trial centers across 140 cities in China[15]. - The company has established a comprehensive chemical technology platform that covers the entire process of small molecule drug research, development, and production, enhancing its competitive advantage in the pharmaceutical R&D service market[31]. - The company has strengthened its integrated service platform through international acquisitions, enhancing service capabilities and R&D efficiency, exemplified by the acquisition of a production base in Cramlington, UK[35]. Strategic Initiatives - The company aims to accelerate drug innovation and become a global leader in multi-therapy drug development services[10]. - The company is focused on enhancing its service platform's synergy through vertical and horizontal integration in drug development[10]. - The company has committed to the Science Based Targets initiative (SBTi) to align its carbon reduction goals with international climate agreements[12]. - The company aims to enhance its integrated drug development service platform, focusing on small molecule research while accelerating the development of large molecule and cell/gene therapy services[40]. - The company plans to expand its laboratory chemistry capabilities and strengthen its CDMO services in small molecules, with a strategic focus on technology investment and service content expansion[41]. Acquisitions and Investments - The company acquired 100% equity of Beijing Ankai Yibo Biotechnology Co., Ltd. to enhance its capabilities in drug safety evaluation and biological sciences[13]. - The acquisition of Aesica Pharmaceuticals Limited was completed in January 2022 for approximately GBP 55 million (about RMB 473.35 million), enhancing the company's CDMO service platform[26]. - Pharmaron Manufacturing Services (US) LLC acquired the Coventry API production facility in Rhode Island for approximately $31.5 million (RMB 210.6 million), completed on July 1, 2022[78]. - The company completed the acquisition of Pharmaron Manufacturing Services (UK) Ltd for a cash consideration of GBP 58,052,000 (approximately RMB 500,837,000) on January 7, 2022[154]. Market Outlook - The global pharmaceutical market's R&D and production investment was approximately $566.1 billion in 2021, projected to reach $726.1 billion by 2026, with a CAGR of 6.5%[37]. - The Chinese pharmaceutical market's R&D and production investment was about RMB 562 billion in 2021, expected to grow to RMB 956.6 billion by 2026, reflecting a CAGR of 11.2%[37]. - The global pharmaceutical R&D and production outsourcing service market was valued at approximately $140.3 billion in 2021, anticipated to reach $247.7 billion by 2026, with a CAGR of 12%[37]. - The company aims to leverage its international operational experience to provide customized services and solutions in gene and cell therapy development[34]. Risk Management - The company faces potential risks, including a decline in demand for drug development services, which could lead to clients postponing project development or cutting research budgets, adversely affecting the company's performance and outlook[43]. - The company operates in a highly regulated environment, with strict legal and industry standards governing drug development and production, and must continuously meet regulatory requirements to avoid penalties or loss of operating qualifications[46]. - The company is committed to complying with increasingly stringent environmental regulations, which may increase compliance costs[47]. Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect and enhance shareholder interests[49]. - The management team consists of experienced professionals, with over 30 years in the pharmaceutical industry, ensuring effective leadership and strategic direction for the company[35]. - The audit committee has reviewed the interim financial information and confirmed compliance with applicable accounting principles and sufficient disclosure[51].

康龙化成（北京）新药技术股份有限公司 2022 年半年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2022 年半年度报告 公告编号：2022-073 2022 年 08 月 1 康龙化成（北京）新药技术股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人 (会计主管人员)李承宗声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |--------------------------------------------------------------------------| | | | 报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 | | 对投资者的实质性承诺， ...

Financial Performance - In 2021, the company achieved revenue of RMB 7,443.8 million, a 45.0% increase compared to the previous year[8]. - The net profit attributable to shareholders was RMB 1,661.0 million, reflecting a growth of 41.7% year-on-year[8]. - The net cash flow from operating activities reached RMB 2,058.0 million, up 24.8% from the previous year[8]. - Total revenue for the year ended December 31, 2021, was approximately RMB 7,443.8 million, an increase of 45.0% compared to RMB 5,133.6 million for the year ended December 31, 2020[15]. - Gross profit for the year ended December 31, 2021, was approximately RMB 2,672.0 million, representing a 39.5% increase from RMB 1,916.1 million in 2020[15]. - Profit attributable to equity holders of the parent for the year ended December 31, 2021, was approximately RMB 1,661.0 million, up 41.7% from RMB 1,172.4 million in 2020[16]. - Net cash flow from operating activities for the year ended December 31, 2021, was approximately RMB 2,058.0 million, an increase of 24.8% compared to RMB 1,648.6 million in 2020[16]. - The company reported a diluted earnings per share of RMB 2.0537 for the year ended December 31, 2021, compared to RMB 1.4781 in 2020[17]. Asset and Equity Growth - By the end of 2021, total assets amounted to RMB 18,389.1 million, representing a 54.4% increase since the beginning of the year[8]. - The equity attributable to shareholders was RMB 10,129.2 million, which is a 14.2% increase from the start of the year[8]. - Total assets increased from RMB 4,143,664 thousand in 2017 to RMB 18,389,124 thousand in 2021, representing a growth of 343%[18]. - The equity attributable to the parent company grew from RMB 1,985,486 thousand in 2017 to RMB 10,129,241 thousand in 2021, marking a 410% increase[18]. - The leverage ratio improved significantly from 51.8% in 2017 to 44.0% in 2021, indicating a reduction in financial risk[18]. Client and Market Engagement - The company provided services to over 2,000 clients, including 800 new clients, and participated in 565 drug discovery projects in 2021[9]. - The company was involved in 77 domestic IND or NDA projects, with 56 projects submitted simultaneously in the US and other countries[9]. - In 2021, approximately 90% of the company's revenue came from a large, diverse, and loyal customer base, with 19.0% of revenue derived from the top 20 global pharmaceutical companies[29]. - Revenue from North American customers accounted for 64.2%, European customers (including the UK) contributed 15.6%, Chinese customers represented 17.1%, and other regions made up 3.1% of total revenue[29]. - The company introduced over 800 new customers in 2021, leading to a decrease in revenue concentration from the top 20 customers from 41.1% in 2020 to 33.8% in 2021[29]. Strategic Acquisitions and Expansion - The company expanded its international operations, acquiring Absorption Systems and Allergan Biologics Limited to enhance its capabilities in CGT services[11]. - The recent acquisition of a small molecule API commercialization facility in Cramlington, UK, aims to create a full industry chain service in chemical and production[11]. - The company plans to expand laboratory space in the UK and the US to meet growing business demands, including new laboratories in Boston and expansions in San Diego and Exton[12]. - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately GBP 55 million (about RMB 47.3 million), enhancing its small molecule CDMO service platform[40]. - The company acquired 100% equity in Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd. for RMB 205.7 million, which has become a wholly-owned subsidiary[39]. Research and Development Focus - The company is focused on enhancing its capabilities in large molecule drugs and cell and gene therapy, aiming to become a global leader in multi-therapy drug development services[23]. - The company plans to launch a new CDMO platform for large molecule drug development and production, with an expected capacity of 70,000 square meters to be operational in 2023[27]. - The company is expanding its clinical research services, integrating platforms for both domestic and international clinical trials[27]. - The company is enhancing its capabilities in gene therapy and cell therapy, including the development of various analytical methods for DNA and RNA[28]. - The company is committed to providing high-level R&D services to assist partners in successfully developing new drugs, contributing to life sciences[19]. Sustainability and ESG Initiatives - The company has set sustainable development goals for 2021-2025, improving its ESG rating from BB in 2020 to BBB in 2021[13]. - The management team emphasized a focus on sustainability initiatives, aiming for a 15% reduction in carbon emissions by 2025[46]. - The company emphasizes environmental protection, health, safety, and intellectual property rights, ensuring robust protection for client IP, which has garnered widespread recognition and trust[51]. Corporate Governance and Management - The board proposed a final cash dividend of RMB 4.5 per share for the year ended December 31, 2021, totaling approximately RMB 357.4 million[16]. - The board of directors is committed to maintaining high levels of corporate governance, which is crucial for the group's development and safeguarding shareholder interests[85]. - The company has adhered to the corporate governance code during the relevant period from January 1, 2021, to December 31, 2021[85]. - The board consists of 11 members, including 9 males and 2 females, with diverse educational backgrounds and skills in various fields such as chemistry, business management, and law[87]. - The company emphasizes the importance of board diversity, considering factors like gender, age, and professional experience in its appointments[86]. Risk Management and Compliance - The company has established a risk management system aimed at improving risk prevention capabilities and promoting sustainable development[111]. - The internal audit system is designed to enhance the quality and efficiency of internal audits and improve the company's supervision and risk control mechanisms[111]. - The company has implemented a tiered management approach for comprehensive risk management, involving the board of directors, audit committee, and various functional departments[112]. - The company has conducted eight meetings of the supervisory board as of the report date[108]. - The company has established early warning and emergency response mechanisms to manage major risks and unexpected events[111]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to 1.44 billion[46]. - The company plans to increase its workforce by 10% to support growth initiatives[46]. - The company aims to enhance shareholder value through a share buyback program, allocating 50 million for this initiative in 2022[73]. - The company plans to implement strategic market strategies tailored to the characteristics of the Chinese market to accumulate customer resources and enhance competitiveness[57]. - The company recognizes the risk of a potential decline in demand for drug development services, which could adversely affect operational performance if the global pharmaceutical market growth slows[58].

Financial Performance - The company's revenue for Q1 2022 was CNY 2,102,899,933.93, representing a 41.19% increase compared to CNY 1,489,385,309.64 in the same period last year[4]. - Net profit attributable to shareholders was CNY 249,086,573.60, a slight increase of 1.31% from CNY 245,874,010.35 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 310,563,849.47, reflecting a 30.83% increase from CNY 237,376,010.22 in the previous year[4]. - Operating revenue for the reporting period reached ¥2,102,899,933.93, an increase of 41.19% compared to ¥1,489,385,309.64 in the same period last year[9]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥310,563,849.47, reflecting a growth of 30.83% from ¥237,376,010.22 year-on-year[9]. - The company reported a total profit of $316.18 million, compared to $282.48 million in the previous period, marking an increase of 11.96%[34]. - The adjusted net profit attributable to the parent company for the first quarter of 2022 was RMB 364,396 thousand, a significant increase of 39.1% year-over-year[47]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 417,792,056.81, down 16.27% from CNY 498,953,761.05 in the same quarter last year[4]. - The total assets at the end of the reporting period were CNY 18,660,920,785.51, a 1.48% increase from CNY 18,389,124,353.35 at the end of the previous year[4]. - The company has shown a strong increase in cash and cash equivalents, with current assets totaling CNY 7,646,204,942.02, down from CNY 8,643,502,127.97, indicating a decrease of about 11.5%[22]. - The company’s cash and cash equivalents were RMB 2,873,493 thousand as of March 31, 2022, down from RMB 3,526,577 thousand at the end of 2021, indicating a decrease of about 18.5%[43]. Expenses and Liabilities - The company's cash flow from financing activities is -$298.11 million, a decrease from $285.02 million in the previous period, indicating a decline of 204.73%[41]. - Operating costs increased by 44.77% to ¥1,407,271,726.88, aligning with the revenue growth[10]. - The company reported a significant rise in financial expenses, up 416.87% to ¥40,234,145.81, primarily due to increased interest expenses[11]. - Total liabilities increased to CNY 8,316,165,204.05 from CNY 8,093,817,609.58, reflecting a rise of approximately 2.8%[26]. Shareholder Information - The top ten shareholders hold a combined 66.77% of the company's shares, with the largest shareholder owning 18.68%[12]. - The top ten unrestricted shareholders hold a total of 448,000,000 shares, with Shenzhen Xinchongkang Investment Partnership holding the largest share of 148,335,300 shares[14]. - The company’s major shareholders include individuals with significant connections, such as Mr. Lou Xiaoqiang, who holds 100% of Ningbo Longtai Kang Investment Management Co., Ltd.[15]. Research and Development - Research and development expenses increased by 36.27% to ¥39,647,299.50 from ¥29,095,136.05 year-on-year, indicating a commitment to enhancing R&D capabilities[11]. - The company reported a net investment loss of CNY 7,402,982.10 from joint ventures and associates, compared to a loss of CNY 344,610.97 in the previous period[77]. Acquisitions and Integrations - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately £55 million (around RMB 47.34 million), enhancing its CDMO service capabilities[18]. - The integration of clinical research services through Kanglong Chemical (Chengdu) Clinical Research Service Co., Ltd. aims to optimize clinical R&D capabilities and improve service quality[19]. Government Support - The company received government subsidies amounting to CNY 9,391,153.38 during the reporting period[6].

康龙化成（北京）新药技术股份有限公司 2021 年年度报告全文 1 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2021 年年度报告 公告编号：2022-023 2022 年 03 月 康龙化成（北京）新药技术股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人(会 计主管人员)李承宗声明：保证本年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 戴立信 独立董事 因疫情管控不便参会 余坚 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"中 ...

Financial Performance - Total revenue for the six months ended June 30, 2021, was approximately RMB 3,285.5 million, an increase of 49.8% compared to RMB 2,193.2 million for the same period in 2020[7]. - Gross profit for the same period was RMB 1,189.7 million, reflecting a 49.8% increase from RMB 794.4 million in the previous year[7]. - Profit attributable to equity holders of the parent was approximately RMB 564.8 million, up 17.9% from RMB 479.0 million for the six months ended June 30, 2020[8]. - Adjusted net profit under non-IFRS was RMB 651.4 million, representing a 50.9% increase from RMB 431.6 million in the prior year[7]. - Net cash flow from operating activities was approximately RMB 845.1 million, an increase of 36.8% compared to RMB 617.9 million for the same period in 2020[8]. - The company did not declare any interim dividend for the six months ended June 30, 2021[8]. - The company achieved a revenue of RMB 3,285.5 million, representing a 49.8% increase compared to the same period last year[14]. - Gross profit reached RMB 1,189.7 million, with a gross margin of 36.2%[14]. - Net profit attributable to the parent company was RMB 564.8 million, an increase of 17.9% year-on-year[14]. - Adjusted net profit attributable to the parent company was RMB 651.4 million, reflecting a 50.9% year-on-year growth[14]. Business Expansion and Services - The company is focused on expanding its capabilities in large molecule and cell and gene therapy research services[9]. - The company aims to become a global leader in multi-therapy drug development services[9]. - The business model includes laboratory services, CMC (small molecule CDMO) services, clinical research services, and large molecule and cell and gene therapy services[9]. - The company has established an integrated research and development service platform covering the entire drug development process and commercialization phase[9]. - The company has expanded its service offerings to include CMC (small molecule CDMO) services and clinical research services to meet customer demands in drug development[10]. - The acquisition of Absorption Systems and Allergan Biologics Limited has enhanced the company's capabilities in large molecule drug and cell and gene therapy services[10]. - The company provides comprehensive drug safety evaluation services that comply with GLP regulations from FDA, NMPA, and OECD, facilitating clinical trial applications for global clients[10]. - The clinical research services include regulatory and compliance registration, medical affairs, clinical operations, data management, and pharmacovigilance, with a focus on both domestic and international markets[12]. - The company has established a fully integrated clinical development service platform, enabling simultaneous IND submissions in China, the US, and Europe[12]. - The CMC CDMO services cover various stages of drug development, including process development and small-scale production, supporting clinical trials from Phase I to Phase III[11]. - The company has a global presence with facilities in Tianjin, Shaoxing, Ningbo, and the UK, continuously enhancing production capacity to meet international quality standards[11]. - The company’s laboratory services include DMPK/ADME and bioanalysis, crucial for small molecule drug development[11]. - The integration of services and technological advancements has led to a rapid increase in revenue from clinical research services[12]. - The company is accelerating the construction of its macromolecule drug CDMO platform, with a new facility in Hangzhou Bay covering nearly 70,000 square meters[14]. - The CDMO services include a full range of processes for cell and gene therapy products, supported by a license from the UK MHRA[14]. - The company is expanding its collaboration with domestic and international pharmaceutical and biopharmaceutical R&D enterprises[14]. Workforce and Human Resources - The company has a total workforce of 12,776 employees as of June 30, 2021, with 11,400 in R&D, production technology, and clinical services, representing 89.2% of the total[15]. - The company’s laboratory services workforce increased by 565 to 6,122 employees as of June 30, 2021, to meet growing business demands[16]. - As of June 30, 2021, the company expanded its CMC (small molecule CDMO) service team to 2,160 employees, an increase of 226 employees compared to December 31, 2020[17]. - The company increased its clinical research service workforce to 2,848 employees as of June 30, 2021, an increase of 640 employees from December 31, 2020[17]. Financial Position and Investments - The company raised approximately RMB 3,776 million from the issuance of zero-coupon convertible bonds, which will be used to expand drug development and production capacity[16]. - The company reported a leverage ratio of 44.2% as of June 30, 2021, compared to 25.0% on December 31, 2020[23]. - The net book value of mortgaged properties, plants, and equipment was approximately RMB 419.6 million as of June 30, 2021, compared to RMB 405.6 million as of December 31, 2020[23]. - The company had no significant contingent liabilities as of June 30, 2021[23]. - The company has established strong partnerships with top pharmaceutical and biotech companies globally, enhancing its reputation in the pharmaceutical R&D service industry[23]. - The company’s core technology focuses on providing a comprehensive drug development platform, which includes integrated CRO+CDMO services[23]. - The company has established a comprehensive chemical technology platform that spans the entire drug development process, including drug discovery, development, and production services[24]. - The company operates 17 entities globally, including locations in China, the UK, and the US, enhancing customer communication and regulatory compliance[25]. - The company has strengthened its global DMPK/ADME service network through the acquisition of Absorption Systems, solidifying its leading position in integrated DMPK services[24]. Market Trends and Strategic Focus - The demand for pharmaceutical R&D services in China is strong, driven by the shift from generic drugs to innovative drugs, making it one of the fastest-growing markets globally[27]. - The company aims to leverage the strong growth momentum in China's pharmaceutical R&D industry to further solidify its market leadership[27]. - The trend of pharmaceutical companies opting for R&D outsourcing to reduce costs and enhance efficiency is becoming more prevalent[28]. - The global drug service market is projected to grow from $99.9 billion in 2020 to $149.8 billion by 2024, with a compound annual growth rate (CAGR) of 10.7%[29]. - The Chinese drug service market is expected to increase from $12 billion in 2020 to $32.7 billion by 2024, representing a growth rate that is double that of the global market[29]. - The company aims to enhance its integrated drug development service platform and expand capabilities in large molecule drugs and cell and gene therapies[30]. - The company aims to strengthen its leadership in small molecule R&D services and enhance its technology and global expansion efforts[31]. Corporate Governance and Compliance - The company has committed to maintaining high levels of corporate governance, which is deemed crucial for the group's development and shareholder interests[38]. - The company has adopted the standard code of conduct for securities trading as per the listing rules, ensuring all directors and supervisors complied during the reporting period[39]. - The audit committee has reviewed the interim financial information and confirmed compliance with applicable accounting principles and sufficient disclosure[40]. - The company is actively monitoring trends in applicable policies and regulations to ensure ongoing compliance[36]. - The company emphasizes the importance of service quality and customer satisfaction as key factors for business growth and client retention[37]. Shareholder Structure and Incentives - The company has a significant shareholder structure with multiple entities holding substantial stakes, including Shenzhen Xincheng Investment Partnership with 157,142,855 A shares[45]. - The total percentage of shares held by major shareholders indicates a concentrated ownership structure, with the top three shareholders holding over 60% of the total shares[43]. - The company has established a long-term incentive mechanism to attract and retain talent through the A-share incentive plan[58]. - The incentive plan aims to align the interests of shareholders and employees, promoting the company's long-term development strategy[58]. - The company has a total of 227 individuals who have been granted restricted A-shares under the incentive plan, including senior management and key technical personnel[58]. Acquisitions and Strategic Investments - The company completed the acquisition of Allergan Biologics Limited in Q2 2021 to enhance its global cell and gene therapy service capabilities[31]. - The company acquired a 55% stake in Enyuan Pharmaceutical Technology (Beijing) Co., Ltd. for RMB 55,000,000, enhancing its control over the subsidiary[67]. - The company acquired a 38.42% stake in Zhaoqing Chuangya Biotechnology Co., Ltd for RMB 68,620,000 and subsequently increased its registered capital by RMB 41,400,000, resulting in a controlling interest of 50.01%[135]. - The acquisition of Pharmaron Biologics (UK) Ltd was completed for a cash consideration of USD 154,458,000 (approximately RMB 998,912,000), with the identifiable net assets valued at RMB 365,885,000 and goodwill of RMB 633,027,000 recognized[132].

康龙化成（北京）新药技术股份有限公司 2021 年半年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2021 年半年度报告 公告编号：2021-072 2021 年 08 月 1 康龙化成（北京）新药技术股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人(会 计主管人员)李承宗声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司对 投资者的实质性承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和应对 措施"部分 ...